A Study of Ki 67 Immunostaining in Prostate Carcinomas: Correlation with Gleason’s Score
DOI:
https://doi.org/10.21276/apalm.2008Keywords:
Prostate cancer, Ki -67, Gleason’s scoreAbstract
Background: One of the most common causes of carcinoma deaths among men is prostate cancer. In view of the above, early diagnosis and effective treatment of the disease are immensely important. The increasing number of options for the treatment of prostate cancer has made the prognostic evaluation of the disease even more important. Proliferation plays an important role in the clinical behaviour of prostate cancer. Ki-67 binding, is an objective measurement of cell proliferation which significantly aids in the management of the prostate patients. Gleason grading describes the aggressiveness of prostate cancer. The Objectives was to study the immunostaining patterns of Ki-67 in prostate cancers and to compare the results with Gleason's score.
Methods: Fifty cases of histopathologically proven prostate carcinomas diagnosed on needle biopsies and transurethral resection specimens was studied in JSS medical college and hospital, mysore for a period of 3years and histopathological grade was assessed using Gleason grading system. Immunohistochemistry (IHC) for Ki-67 was done on paraffin embedded wax sections.
Result: Ki-67 was positive in 49/50 cases (98%). The range of Ki-67 score was 0 to 94%. No statistically significant association was seen with Ki-67 and gleasons scores (P=0.277).
Conclusion: Proliferation has been recognized as a distinct hallmark of cancer and acts as an important determinant of cancer outcome. As Ki-67 can be used to objectively measure this, it can be included in the pool of prognostic markers like tumor volume, histopathological grade and surgical margins.
References
2. Madani SH, Ameli S, Khazaei S, Kanani M, Izadi B. Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer. Indian J Pathol Microbiol 2011;54:688-91
3. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58–64.
4. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. Part 1. 1966; 50(3): 125–8.
5. Mellinger GT, Gleason D, Bailar J. The histology and prognosis of prostatic cancer. J Urol 1967; 97(2):331–7.
6. Poulos CK, Daggy JK, Cheng L. Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites. Mod Pathol 2005; 18: 228–34.
7. Tsukamoto T, Kumamoto Y, Umehara T, Takahashi A, Shimazaki J, Ohshima H et al. Clinical study of bone-related relapse in prostate carcinoma. Adv Exp Med and Biol 1992; 324: 283–93.
8. Shirley SE, Escoffery CT, Sargeant LA, Tulloch T. Clinicopathological features of prostate cancer in Jamaican men. BJU International 2002; 89:390-95.
9. Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. J Urol 2002; 168:1980-84.
10. E. Muñoz, F. Gómez, J.I. Paz, I.Casado, J.M. Silva, M.T. Corcuera, M. J. Alonso. Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation. European Journal of histochemistry 2003;47(2):123-28
11. Rashed HE, Kateb M.I, Ragab A , Shaker SS. Evaluation of minimal prostate cancer in needle biopsy specimens using AMACR (P5045), p63 and ki67. Life Sci J 2012; 9(4): 12-21
12. Theodoropoulos VE, Tsigka A, Mihalopoulou A,Tsoukala V, Lazaris AC, Patsouris E. Evaluation of neuroendocrine staining and androgenreceptor expression in incidental prostatic adenocarcinoma: Prognostic implications. Urology 2005;66:897-902.
13. Nilsson S, Nordgren H, Karlberg L, Harvig B, Busch C, Hall T, et al. Expression of estramustine-binding protein (EMBP) and the proliferation-associated antigen Ki-67 in prostatic carcinomas. Scand J Urol Nephrol 1988;110:31-7.
14. Murti K, Warli SM, Laksmi LI. Relations between KI-67 immunohistochemistry expression with histopathology grading and prostate-specific antigen (PSA) values in adenocarcinoma prostate at Dr H. Adam Malik Hospital, Medan Indonesia. Bali Med J 2017; 6(2):289-293
15. Thompson SJ, Mellon K, Charlton RG, Marsh C, Robinson M, Neal DE. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol. 1992; 69:609–13.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Roopa Urs A.N, Suchitha S, Manjunath G V, Hugara Siddalingappa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
